Organization | EvergreenHealth

EvergreenHealth Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Founded: Kirkland WA United States (1972)

Organization Overview

First Clinical Trial

2005

NCT00260793

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Agarwal, Pinky, M.D. | Brown, Theodore R., M.D., MPH | Burdick, Daniel, M.D. | Daniel Burdick, MD | Daniel Burdick, M.D. | EvergreenHealth | Evergreen Health | Evergreen Healthcare | EvergreenHealth Multiple Sclerosis Center | EvergreenHealth Urology & Urogynecology Care | Evergreen Hematology & Oncology | MS Center at Evergreen | MS Center at Evergreen Healthcare | Theodore R. Brown, M.D., MPH | Theodore R. Brown, MD MPH | Virginia Simnad

Active Ingredients

Drugs in Phase 4 Trials (7)

abobotulinumtoxinA (Dysport) (1 trial)

dalfampridine (ampyra) (1 trial)

diclofenac (voltaren) (1 trial)

lidocaine (xylocaine) (1 trial)

mirabegron (myrbetriq) (2 trials)

suvorexant (belsomra) (2 trials)

tetracaine (pontocaine) (1 trial)

Drugs in Phase 3 Trials (5)

azithromycin (zithromax) (1 trial)

duloxetine (Cymbalta) (1 trial)

ethambutol (myambutol) (1 trial)

rifampin (1 trial)

ropinirole (Requip) (1 trial)

Drugs in Phase 1 Trials (2)

rtl1000 (1 trial)

xmt-1001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Dyspareunia (Phase 4)

Fatigue (Phase 4)

Lung Neoplasms (Phase 1)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Mycobacterium avium-intracellulare Infection (Phase 3)

Mycobacterium Infections (Phase 3)

Mycobacterium Infections, Nontuberculous (Phase 3)

Parkinson Disease (Phase 4)

Pelvic Pain (Phase 4)

Sclerosis (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 4)

Small Cell Lung Carcinoma (Phase 1)

Urinary Bladder, Overactive (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 14